Abstract:Immunotherapy with anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) monoclonal antibodies has become routine in the treatment of many kinds of human cancers, such as lung cancer, intestinal cancer, and melanoma. The PD-1/PD-L1 pathway inhibits T cell activation in the micro-environment, making it an attractive target against cancer. Wild-type (WT) PD-1 ectodomain has been shown to have difficulty blocking PD-1/PD-L1 mixture formation due to its low affinity. The present work uses three-dimensional (3D) crystal complex structures to analyze the interaction by which PD-1 binds to PD-Ll or PD-L2. It also reports on a theoretical study of the binding mode between PD-1 and its clinical antibody Opdivo. Based on the theoretical binding analysis of PD-1 and its ligands (i.e., PD-Ll and PD-L2) or antibody (Opdivo), a small-content, epitope-oriented mammalian cell library was established for PD-1. After three rounds of cell sorting, the decoy PD-1 mutant 463, which presented a higher affinity than WT PD-1 to the PD-Ll (the affinity has increased by almost three orders of magnitude) was screened out. It exhibited an inhibitory effect against PD-1 to prevent it from forming mixtures with PD-L1, which was similar to the effect of the commercial anti-PD-Ll antibody atezolizumab (ATE). The median effective concentration (EC50) value of the decoy mutant was 0.031 mu g.mL(-1) in comparison with 0.063 mu g.mL(-1) for ATE; both values were much lower than that of WT PD-1, at 2.571 mu g.mL(-)(1) . The 463 decoy mutant reversed the inhibitory function of PD-1 in T cell activation; furthermore, 10 mg.kg(-1) of 463 inhibited about 75% of tumor growth in vivo in a MC38 transgenic xenograft mice model, which was similar to the activity of ATE. More interestingly, an even lower dose of 463 (2 mg.kg(-1)) showed a better effect than 10 mg.kg(-1) of WT PD-1. This work offers the decoy 463 with an improved curative effect, which holds potential to become a good option against PD-1/PD-L1-related cancers. (C) 2021 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.

Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.

The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD)

Computational analysis of hot spots and binding mechanism in the PD-1/PD-L1 interaction

Understanding the Structural and Energetic Basis of PD-1 and Monoclonal Antibodies Bound to PD-L1: A Molecular Modeling Perspective.

Residue Specific Binding Mechanisms of PD-1 to Its Monoclonal Antibodies by Computational Alanine Scanning

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

Ultra-stable Biomembrane Force Probe for Accurately Determining Slow Dissociation Kinetics of PD-1 Blockade Antibodies on Single Living Cells.

Residue-specific binding mechanisms of PD-L1 to its monoclonal antibodies by computational alanine scanning

Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: a comparative study of molecular dynamics simulations.

Shedding light on cancer immunology at the molecular level: A quantum biochemistry study of representative PD-1/PD-L1 conformations

Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: a comparative study of molecular dynamics simulations

A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules

Mechanical force regulates ligand binding and function of PD-1

High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library

Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor

Palmitoylation is critically required for cancer intrinsic PD-1 expression and functions

Structural Basis of a Novel PD-L1 Nanobody for Immune Checkpoint Blockade

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1

Computational analysis of PD-L1 dimerization mechanism induced by small molecules and potential dynamical properties

Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?

PD-1 regulation in immune homeostasis and immunotherapy